Physiologically based pharmacokinetics and cancer risk assessment.
about
A Workflow for Global Sensitivity Analysis of PBPK Models.In silico methods for physiologically based biokinetic models describing bioactivation and detoxification of coumarin and estragole: implications for risk assessment.Have physiologically-based pharmacokinetic models delivered?Translational research to develop a human PBPK models tool kit-volatile organic compounds (VOCs).
P2860
Physiologically based pharmacokinetics and cancer risk assessment.
description
1994 nî lūn-bûn
@nan
1994 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Physiologically based pharmacokinetics and cancer risk assessment.
@ast
Physiologically based pharmacokinetics and cancer risk assessment.
@en
type
label
Physiologically based pharmacokinetics and cancer risk assessment.
@ast
Physiologically based pharmacokinetics and cancer risk assessment.
@en
prefLabel
Physiologically based pharmacokinetics and cancer risk assessment.
@ast
Physiologically based pharmacokinetics and cancer risk assessment.
@en
P2860
P356
P1476
Physiologically based pharmacokinetics and cancer risk assessment.
@en
P2093
Andersen ME
Krishnan K
P2860
P304
P356
10.1289/EHP.94102S1103
P478
102 Suppl 1
P577
1994-01-01T00:00:00Z